셀트리온
Korea's leading biosimilar maker, founded 2002. Its Remsima anti-TNF therapy was the world's first biosimilar approved by the European Medicines Agency.
No Celltrion Group briefs yet.
Korea's pioneering biosimilar company. Developed Remsima, the world's first antibody biosimilar. Expanding into novel biologics and global direct sales through Celltrion Healthcare integration.